Revvity, Inc. (NYSE:RVTY) Shares Bought by Primecap Management Co. CA

Primecap Management Co. CA raised its position in Revvity, Inc. (NYSE:RVTY - Free Report) by 2.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 951,885 shares of the company's stock after acquiring an additional 18,580 shares during the quarter. Primecap Management Co. CA owned approximately 0.78% of Revvity worth $106,240,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Janus Henderson Group PLC grew its position in Revvity by 1.7% in the 3rd quarter. Janus Henderson Group PLC now owns 6,335,302 shares of the company's stock valued at $809,332,000 after acquiring an additional 108,401 shares in the last quarter. State Street Corp grew its position in Revvity by 0.3% in the 3rd quarter. State Street Corp now owns 5,180,169 shares of the company's stock valued at $661,767,000 after acquiring an additional 17,832 shares in the last quarter. Geode Capital Management LLC grew its position in Revvity by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 2,863,793 shares of the company's stock valued at $364,569,000 after acquiring an additional 25,078 shares in the last quarter. EdgePoint Investment Group Inc. boosted its stake in shares of Revvity by 34.6% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 2,685,775 shares of the company's stock valued at $343,108,000 after buying an additional 690,534 shares during the period. Finally, RGM Capital LLC boosted its stake in shares of Revvity by 3.2% in the 3rd quarter. RGM Capital LLC now owns 980,858 shares of the company's stock valued at $125,305,000 after buying an additional 30,000 shares during the period. 86.65% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Bank of America upgraded Revvity from a "neutral" rating to a "buy" rating and set a $138.00 price objective for the company in a research note on Friday, December 13th. Raymond James reiterated an "outperform" rating and issued a $145.00 price objective (up previously from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Barclays lifted their price objective on Revvity from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. KeyCorp lifted their price objective on Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Finally, Sanford C. Bernstein cut Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price objective for the company. in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $136.25.

Revvity Stock Performance

NYSE RVTY traded up $0.20 on Friday, reaching $107.18. The stock had a trading volume of 1,281,291 shares, compared to its average volume of 850,141. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. Revvity, Inc. has a 12-month low of $97.32 and a 12-month high of $129.50. The business's 50-day moving average price is $116.44 and its 200 day moving average price is $117.56. The stock has a market cap of $12.88 billion, a P/E ratio of 48.50, a price-to-earnings-growth ratio of 3.82 and a beta of 1.06.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period in the previous year, the company earned $1.25 earnings per share. As a group, equities analysts expect that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity's dividend payout ratio is currently 12.67%.

Insider Buying and Selling at Revvity

In other news, insider Tajinder S. Vohra sold 5,492 shares of the business's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total value of $641,520.52. Following the transaction, the insider now owns 19,652 shares of the company's stock, valued at approximately $2,295,550.12. The trade was a 21.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Joel S. Goldberg sold 15,170 shares of the business's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total value of $1,922,494.10. Following the completion of the transaction, the insider now directly owns 33,400 shares in the company, valued at approximately $4,232,782. The trade was a 31.23 % decrease in their position. The disclosure for this sale can be found here. 0.60% of the stock is owned by company insiders.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.